A股異動 | 青海春天(600381.SH)漲停 擬2.4億元收購三普藥業部分資產
格隆匯12月8日丨青海春天(600381.SH)盤初直線拉昇至漲停,報6.25元,暫成交5778.8萬元,總市值36.7億元。
青海春天7日公告,擬2.4億元收購三普藥業部分資產。通過此次交易,公司將擁有更為豐富、專業的藥品和保健食品生產線,為公司後續穩健、長遠的發展和實現戰略發展目標創造了良好的條件。
目前公司具備完成此次交易的能力,但在短期內將對公司的現金流帶來一定的影響,增加財務壓力。此次收購如能完成,利於公司的後續發展經營。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.